Prostate‐specific antigen‐based prostate cancer screening remains a controversial topic.
Up to now, there is worldwide consensus on the statement that the harms of population …

This review discusses evidence for population‐based screening with contemporary
screening tools. In Europe, prostate‐specific antigen (PSA)‐based screening led to a …

Background Screening for prostate cancer using prostate-specific antigen (PSA) reduces
prostate cancer mortality but can lead to adverse outcomes. We aimed to compare a …

The purpose of this review is to identify clinical risk factors for prostate cancer and to assess
the utility and limitations of our current tools for prostate cancer screening. Prostate-specific …

Purpose: The summary presented herein covers recommendations on the early detection of
prostate cancer and provides a framework to facilitate clinical decision-making in the …

Background Recommendations against prostate-specific antigen (PSA) testing in 2012 have
increased advanced-stage diagnosis and prostate cancer–specific mortality rates. Objective …

Background Stockholm3 is a risk model that combines the prostate-specific antigen (PSA)
test, other plasma protein biomarkers, single nucleotide polymorphisms, and clinical …

CONTEXT: Widespread mass screening of prostate cancer (PCa) is not recommended
because the balance between benefits and harms is still not well established. The achieved …

Context Overdiagnosis as the argument to stop prostate cancer (PCa) screening is less valid
since the introduction of new technologies such as risk calculators (RCs) and magnetic …

The European Randomised Study of Screening for Prostate Cancer (ERSPC) showed that
Prostate‐Specific Antigen (PSA) based screening results in a significant prostate cancer …